News
ONCT
0.5266
0.00%
0.0000
Weekly Report: what happened at ONCT last week (1230-0103)?
Weekly Report · 01/06 12:00
Weekly Report: what happened at ONCT last week (1223-1227)?
Weekly Report · 12/30/2024 11:52
More
Webull provides a variety of real-time ONCT stock news. You can receive the latest news about Oncternal Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.